Qureight has raised around £7m in Series A funding to accelerate the development of treatments for lung and heart diseases.

The Cambridge company’s cloud platform leverages image data analysis and AI technology to help approve the best new drugs.

Its technology is used by hospitals, clinical research organizations, and multinational pharmaceutical companies to find new treatments for complex lung and heart diseases.

Hargreave Hale AIM VCT led the round, with participation from XTX Ventures, Guinness Ventures, and existing investors including Playfair Capital, Meltwind, Ascension Life Fund, and Cambridge Angels.

Complex lung and heart diseases such as idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension currently have limited treatment options and low survival rates.

High-value data from patient scans and records is typically stored in an unstructured format across numerous platforms and databases. Researchers must manually extract relevant data from sources for research, which is a very expensive and time-consuming process.

Built to tackle this complex problem, Qureight’s digital infrastructure stores and manages multiple types of medical data for powerful analytics.

Founder leads coup on BenevolentAI’s board of directors

Qureight has unique healthcare access through NHS England-wide data agreements, and as trials of drugs to treat complex diseases progress, we provide access to CT scans, biomarkers and other trial endpoints to hospitals or clinical research facilities ( can be collected in real-time directly from the CRO. This information is securely collated, structured, and ready for analysis.

Insights from this analysis can be used to examine drug responses and find new endpoints. Structured data can also be used to build virtual trial patients, making it easier to run AI models and compare disparate datasets.

Ultimately, this will enable us to design more resource-efficient clinical trials, improve existing disease treatments, and develop powerful new drugs.

Qureight has ongoing strategic and research alliances with some of the world’s most renowned healthcare, research and pharmaceutical companies, including AstraZeneca, Vicore Pharma and several NHS Trusts.

“10 things I learned when I was 25 still apply today at 35.”

Following the close of this round, Qureight’s new board members include Dr. Debra Barker, an experienced healthcare NED and chief medical officer and former senior vice president of Novartis, and Dr. Debra Barker, CEO of the Animal Care Group and CEO of AstraZeneca; They include Jenny Winter, former vice president;

Consultant thoracic radiologist Dr Simon Walsh has joined the Qureight team as Chief Scientific Officer. He was previously his NIHR Clinician-Scientist at the National Heart and Lung Institute, Imperial College, London, and is now retired Imaging Chair of the European Respiratory Society.

He is also a member of the Fleischner Society, a prestigious global group of 60 leading respiratory scientists and radiologists.

“The closing of our Series A round marks the end of the beginning and the beginning of a new chapter for Qureight, as we focus on developing our platform and developing products in new disease areas,” said the founders. says Dr. Mfuntan Thirai. And the CEO.

“Our mission to extend the lives of patients with lung and heart disease is strengthened by the valuable expertise of our new board of directors and new senior team members, and we look forward to strengthening our strategic biopharmaceutical collaboration.” Masu.”

Lucy Bloomfield, joint manager of Hargreave Hale AIM VCT, commented: “Hargreave Hale AIM VCT has a long tradition of investing in innovative, high-growth companies, and the application of AI in life sciences is an area of ​​particular interest.

“Throughout the investment process, Qureight’s team impressed us with their vision and expertise. We are pleased to be the lead investor in this funding round and look forward to helping Qureight expand its capabilities. I’m looking forward to it.”

HG acquires private equity stake in Acquisition Focus Group